BidaskClub upgraded shares of Tyme Technologies (NASDAQ:TYME) from a strong sell rating to a sell rating in a research note released on Thursday morning.
A number of other analysts have also commented on the company. Zacks Investment Research lowered Tyme Technologies from a hold rating to a sell rating in a report on Thursday, February 15th. HC Wainwright reaffirmed a buy rating and issued a $9.50 target price (up previously from $8.00) on shares of Tyme Technologies in a research report on Thursday, February 8th. Canaccord Genuity started coverage on Tyme Technologies in a research report on Wednesday, January 3rd. They issued a buy rating on the stock. Finally, Evercore ISI started coverage on Tyme Technologies in a research report on Friday, November 17th. They issued an outperform rating and a $7.00 target price on the stock. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock has an average rating of Hold and an average price target of $8.25.
Shares of Tyme Technologies (NASDAQ TYME) opened at $2.68 on Thursday. The company has a market capitalization of $267.47, a PE ratio of -15.76 and a beta of -0.05. Tyme Technologies has a twelve month low of $2.14 and a twelve month high of $9.50.
Several large investors have recently added to or reduced their stakes in TYME. Monashee Investment Management LLC acquired a new position in Tyme Technologies during the fourth quarter worth approximately $128,000. Wells Fargo & Company MN increased its position in Tyme Technologies by 923.9% during the fourth quarter. Wells Fargo & Company MN now owns 29,180 shares of the company’s stock worth $186,000 after buying an additional 26,330 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new position in Tyme Technologies during the fourth quarter worth approximately $198,000. BlueCrest Capital Management Ltd acquired a new position in Tyme Technologies during the fourth quarter worth approximately $247,000. Finally, Family Management Corp acquired a new position in Tyme Technologies during the fourth quarter worth approximately $702,000. 4.09% of the stock is currently owned by institutional investors and hedge funds.
About Tyme Technologies
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.